therapeutics-话题@MedSci

#therapeutics#

68篇内容 | 2520人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1350863, encodeId=84b41350863be, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Dermaliq Therapeutics宣布在评估DLQ02治疗斑块状银屑病的1b/2期试验中向首例患者给药, objectType=article, longId=736627, objectId=8550e36627cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8550e36627cf, replyNumber=0, likeNumber=73, createdTime=2022-08-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8550e36627cf, moduleTitle=Dermaliq Therapeutics宣布在评估DLQ02治疗斑块状银屑病的1b/2期试验中向首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8550e36627cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350862, encodeId=19d71350862b9, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Neuraptive Therapeutics宣布NTX-001预防面瘫的2期试验入组首位患者，并公布NTX-001治疗外伤导致的外周神经损伤的2期研究的最新进展, objectType=article, longId=733070, objectId=b592e3307065, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b592e3307065, replyNumber=0, likeNumber=68, createdTime=2022-07-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b592e3307065, moduleTitle=Neuraptive Therapeutics宣布NTX-001预防面瘫的2期试验入组首位患者，并公布NTX-001治疗外伤导致的外周神经损伤的2期研究的最新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b592e3307065)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350861, encodeId=8ef0135086161, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=ENGRAIL THERAPEUTICS公布ENX-101临床1b研究正面结果, objectType=article, longId=730038, objectId=b83ee300388a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b83ee300388a, replyNumber=0, likeNumber=119, createdTime=2022-06-22, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b83ee300388a, moduleTitle=ENGRAIL THERAPEUTICS公布ENX-101临床1b研究正面结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b83ee300388a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350860, encodeId=28cb1350860dd, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法, objectType=article, longId=294032, objectId=36af294032f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af294032f6, replyNumber=0, likeNumber=72, createdTime=2022-01-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af294032f6, moduleTitle=武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af294032f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350859, encodeId=f5731350859f0, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线, objectType=article, longId=293894, objectId=b4132938940e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4132938940e, replyNumber=0, likeNumber=100, createdTime=2022-01-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4132938940e, moduleTitle=Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4132938940e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350858, encodeId=d974135085886, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Alentis Therapeutics启动旨在治疗肝肾纤维化的首次人体临床试验, objectType=article, longId=293496, objectId=4d0b2934962d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d0b2934962d, replyNumber=0, likeNumber=117, createdTime=2022-01-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d0b2934962d, moduleTitle=Alentis Therapeutics启动旨在治疗肝肾纤维化的首次人体临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d0b2934962d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350857, encodeId=95bb135085ead, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, objectType=article, longId=220575, objectId=ad652205e545, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad652205e545, replyNumber=0, likeNumber=70, createdTime=2021-11-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad652205e545, moduleTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad652205e545)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350856, encodeId=94a713508562a, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法, objectType=article, longId=219603, objectId=6d1621960324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d1621960324, replyNumber=0, likeNumber=84, createdTime=2021-11-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d1621960324, moduleTitle=武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d1621960324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350855, encodeId=885913508554b, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., objectType=article, longId=218899, objectId=169221889999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=169221889999, replyNumber=0, likeNumber=81, createdTime=2021-10-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=169221889999, moduleTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=169221889999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350854, encodeId=e9d01350854c5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=SAB Biotherapeutics宣布，由NIH赞助、有关SAB-185治疗新冠肺炎的ACTIV-2试验获得DSMB评审肯定，即将进入3期阶段, objectType=article, longId=217907, objectId=3c3421e9078a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c3421e9078a, replyNumber=0, likeNumber=98, createdTime=2021-10-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c3421e9078a, moduleTitle=SAB Biotherapeutics宣布，由NIH赞助、有关SAB-185治疗新冠肺炎的ACTIV-2试验获得DSMB评审肯定，即将进入3期阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c3421e9078a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350853, encodeId=4a76135085370, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=RubrYc Therapeutics宣布与iBio, Inc.达成A2轮优先股权融资、合作协议及RTX-003许可, objectType=article, longId=216365, objectId=235721636565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=235721636565, replyNumber=0, likeNumber=59, createdTime=2021-08-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=235721636565, moduleTitle=RubrYc Therapeutics宣布与iBio, Inc.达成A2轮优先股权融资、合作协议及RTX-003许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=235721636565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350852, encodeId=82ff1350852cd, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=辉瑞以 23 亿美元收购抗癌药物公司Trillium Therapeutics，溢价203.8%, objectType=article, longId=216230, objectId=0d962162302d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d962162302d, replyNumber=0, likeNumber=106, createdTime=2021-08-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d962162302d, moduleTitle=辉瑞以 23 亿美元收购抗癌药物公司Trillium Therapeutics，溢价203.8%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d962162302d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350851, encodeId=359913508513c, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议, objectType=article, longId=213183, objectId=364e2131837c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=364e2131837c, replyNumber=0, likeNumber=74, createdTime=2021-06-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=364e2131837c, moduleTitle=LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=364e2131837c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350850, encodeId=a6aa135085083, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=武田将收购Maverick Therapeutics，以推进T细胞接合治疗实体瘤，扩大新型免疫肿瘤产品组合, objectType=article, longId=208266, objectId=376920826667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376920826667, replyNumber=0, likeNumber=88, createdTime=2021-03-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376920826667, moduleTitle=武田将收购Maverick Therapeutics，以推进T细胞接合治疗实体瘤，扩大新型免疫肿瘤产品组合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376920826667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Engrail Therapeutics收购NeuroCycle Therapeutics改进及优化药物以改善中枢神经系统疾病患者生活, objectType=article, longId=206733, objectId=aed0206e3371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aed0206e3371, replyNumber=0, likeNumber=71, createdTime=2021-02-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aed0206e3371, moduleTitle=Engrail Therapeutics收购NeuroCycle Therapeutics改进及优化药物以改善中枢神经系统疾病患者生活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aed0206e3371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350848, encodeId=d9521350848ce, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, objectType=article, longId=206408, objectId=55db20640853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55db20640853, replyNumber=0, likeNumber=84, createdTime=2021-01-31, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55db20640853, moduleTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55db20640853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法, objectType=article, longId=205517, objectId=6a4020551e01, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a4020551e01, replyNumber=0, likeNumber=91, createdTime=2021-01-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a4020551e01, moduleTitle=Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a4020551e01)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350846, encodeId=5e2013508460a, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Vertex和CRISPR Therapeutics的镰状细胞基因疗法已获得PRIME称号, objectType=article, longId=201362, objectId=f56c2013622b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f56c2013622b, replyNumber=0, likeNumber=78, createdTime=2020-09-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f56c2013622b, moduleTitle=Vertex和CRISPR Therapeutics的镰状细胞基因疗法已获得PRIME称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f56c2013622b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350845, encodeId=109913508456c, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=美国国防部授予SAB Biotherapeutics 3560万美元，以推进COVID-19快速反应抗体计划, objectType=article, longId=198945, objectId=9a9b1989454e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9b1989454e, replyNumber=0, likeNumber=132, createdTime=2020-08-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9b1989454e, moduleTitle=美国国防部授予SAB Biotherapeutics 3560万美元，以推进COVID-19快速反应抗体计划, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9b1989454e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350844, encodeId=b4cf1350844af, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Alimentary Pharmacology Therapeutics：幽门螺杆菌感染可降低食道和近端胃的腺癌发生率 , objectType=article, longId=191616, objectId=54c019161677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c019161677, replyNumber=0, likeNumber=59, createdTime=2020-04-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c019161677, moduleTitle=Alimentary Pharmacology Therapeutics：幽门螺杆菌感染可降低食道和近端胃的腺癌发生率 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54c019161677)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

therapeutics

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Dermaliq Therapeutics宣布在评估DLQ02治疗斑块状银屑病的1b/2期试验中向首例患者给药

2022-08-24

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Neuraptive Therapeutics宣布NTX-001预防面瘫的2期试验入组首位患者，并公布NTX-001治疗外伤导致的外周神经损伤的2期研究的最新进展

2022-07-24

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

ENGRAIL THERAPEUTICS公布ENX-101临床1b研究正面结果

2022-06-22

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法

2022-01-17

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线

2022-01-14

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Alentis Therapeutics启动旨在治疗肝肾纤维化的首次人体临床试验

2022-01-07

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据

2021-11-20

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法

2021-11-03

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc.

2021-10-21

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

SAB Biotherapeutics宣布，由NIH赞助、有关SAB-185治疗新冠肺炎的ACTIV-2试验获得DSMB评审肯定，即将进入3期阶段

2021-10-01

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

RubrYc Therapeutics宣布与iBio, Inc.达成A2轮优先股权融资、合作协议及RTX-003许可

2021-08-28

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

辉瑞以 23 亿美元收购抗癌药物公司Trillium Therapeutics，溢价203.8%

2021-08-25

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议

2021-06-26

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

武田将收购Maverick Therapeutics，以推进T细胞接合治疗实体瘤，扩大新型免疫肿瘤产品组合

2021-03-13

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Engrail Therapeutics收购NeuroCycle Therapeutics改进及优化药物以改善中枢神经系统疾病患者生活

2021-02-05

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法

2021-01-31

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法

2021-01-10

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Vertex和CRISPR Therapeutics的镰状细胞基因疗法已获得PRIME称号

2020-09-30

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

美国国防部授予SAB Biotherapeutics 3560万美元，以推进COVID-19快速反应抗体计划

2020-08-09

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Alimentary Pharmacology Therapeutics：幽门螺杆菌感染可降低食道和近端胃的腺癌发生率

2020-04-08

科室
- - 订阅+
  - 更多科室
工具
服务